Screener
Wave Life Sciences WVE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | $7,874 |
| Shareholders’ equity: | ||
| Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | $1,627,209 | $1,616,478 |
| Additional paid-in capital | 248,161 | 228,365 |
| Accumulated other comprehensive loss | (172) | (250) |
| Accumulated deficit | (1,421,678) | (1,326,236) |
| Total shareholders’ equity | $453,520 | $518,357 |
| Total liabilities, Series A preferred shares, and shareholders’ equity | $558,321 | $638,499 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's total equity?
- Wave Life Sciences (WVE) reported total equity of $453.52M in Q2 2026.
- How has Wave Life Sciences's total equity changed year-over-year?
- Wave Life Sciences's total equity increased by 225.7% year-over-year, from $139.27M to $453.52M.
- What is the long-term trend for Wave Life Sciences's total equity?
- Over 5 years (2020 to 2025), Wave Life Sciences's total equity has grown at a 44.3% compound annual growth rate (CAGR), from $82.78M to $518.36M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Wave Life Sciences's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude